Literature DB >> 24395242

Revisiting epilepsy and the electroencephalogram patterns in Angelman syndrome.

Marcio Leyser1, Patricia Sola Penna, Alexandre Cardozo de Almeida, Marcio Moacyr Vasconcelos, Osvaldo J M Nascimento.   

Abstract

Angelman syndrome is a neurogenetic disorder that severely affects global neurodevelopment due to modifications in the structure or functioning of UBE3A gene. Its prevalence ranges from 1:10,000 to 1:40,000. There are four main genetic types of AS transmission. A maternal deletion in 15q11.2-q13 is the most common type. There are three well-established electroencephalogram (EEG) patterns used as an ancillary tool for AS diagnosis. The main objectives are to scrutinize the EEG patterns in Angelman syndrome, their correlation to different types of seizures and to review the role of the EEG as an ancillary screening tool in the diagnosis of clinically suspected patients. Forty-three patients' charts and their previously recorded EEGs were reviewed. A set of 34 patients with deletion type, paternal uniparental disomy type and imprint defect type AS were enrolled. AS diagnosis was confirmed either by fluorescent in situ hybridization test or Methylation Specific-Multiplex Ligation Probe Amplification test. Sequencing of UBE3A was not available. Frequencies and Chi-square tests were used for statistic analysis. Pattern I type EEG was observed in 22 (64.7 %) individuals. Pattern II accounted for 6 (17.6 %); Pattern III was evident in 11 (32.4 %). The three distinguished EEG patterns, more frequently Pattern I, when observed in the appropriate clinical setting, may heighten the index of suspicion for selecting patients who will need a molecular biology test to confirm the diagnosis of AS.

Entities:  

Mesh:

Year:  2014        PMID: 24395242     DOI: 10.1007/s10072-013-1586-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  Angelman syndrome: difficulties in EEG pattern recognition and possible misinterpretations.

Authors:  Kette D Valente; Joaquina Q Andrade; Rosi M Grossmann; Fernando Kok; Cintia Fridman; Célia P Koiffmann; Maria J Marques-Dias
Journal:  Epilepsia       Date:  2003-08       Impact factor: 5.864

2.  Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome.

Authors:  Naoko Uemura; Akiko Matsumoto; Miho Nakamura; Kazuyoshi Watanabe; Tamiko Negoro; Toshiyuki Kumagai; Kiyokuni Miura; Takashi Ohki; Seiji Mizuno; Akihisa Okumura; Kohzaburo Aso; Fumio Hayakawa; Yoko Kondo
Journal:  Brain Dev       Date:  2005-08       Impact factor: 1.961

3.  Angelman syndrome 2005: updated consensus for diagnostic criteria.

Authors:  Charles A Williams; Arthur L Beaudet; Jill Clayton-Smith; Joan H Knoll; Martin Kyllerman; Laura A Laan; R Ellen Magenis; Ann Moncla; Albert A Schinzel; Jane A Summers; Joseph Wagstaff
Journal:  Am J Med Genet A       Date:  2006-03-01       Impact factor: 2.802

4.  Analysis of EEG patterns and genotypes in patients with Angelman syndrome.

Authors:  Martina Vendrame; Tobias Loddenkemper; Marcin Zarowski; Matt Gregas; Hans Shuhaiber; Dean P Sarco; Augusto Morales; Mark Nespeca; Cia Sharpe; Kevin Haas; Gregory Barnes; Daniel Glaze; Sanjeev V Kothare
Journal:  Epilepsy Behav       Date:  2012-02-16       Impact factor: 2.937

5.  Implications of slow waves and shifting epileptiform discharges in Angelman syndrome.

Authors:  Mi-Sun Yum; Eun Hye Lee; Joo-Hyun Kim; Tae-Sung Ko; Han-Wook Yoo
Journal:  Brain Dev       Date:  2012-06-15       Impact factor: 1.961

6.  Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county.

Authors:  M B Petersen; K Brøndum-Nielsen; L K Hansen; K Wulff
Journal:  Am J Med Genet       Date:  1995-06-19

7.  Diagnosis of Angelman syndrome: clinical and EEG criteria.

Authors:  S Buoni; S Grosso; L Pucci; A Fois
Journal:  Brain Dev       Date:  1999-07       Impact factor: 1.961

Review 8.  Angelman syndrome reviewed from a neurophysiological perspective. The UBE3A-GABRB3 hypothesis.

Authors:  B Dan; S G Boyd
Journal:  Neuropediatrics       Date:  2003-08       Impact factor: 1.947

Review 9.  Genomic imprinting disorders in humans: a mini-review.

Authors:  Merlin G Butler
Journal:  J Assist Reprod Genet       Date:  2009-10-21       Impact factor: 3.412

Review 10.  Epilepsy in Angelman syndrome.

Authors:  Karine Pelc; Stewart G Boyd; Guy Cheron; Bernard Dan
Journal:  Seizure       Date:  2007-09-29       Impact factor: 3.184

View more
  7 in total

1.  Environmental Enrichment Improves Behavioral Abnormalities in a Mouse Model of Angelman Syndrome.

Authors:  Imran Jamal; Vipendra Kumar; Naman Vatsa; Brijesh Kumar Singh; Shashi Shekhar; Ankit Sharma; Nihar Ranjan Jana
Journal:  Mol Neurobiol       Date:  2016-09-01       Impact factor: 5.590

Review 2.  Reprogramming patient-derived cells to study the epilepsies.

Authors:  Jack M Parent; Stewart A Anderson
Journal:  Nat Neurosci       Date:  2015-02-24       Impact factor: 24.884

Review 3.  Epilepsy in Angelman syndrome: A scoping review.

Authors:  Debopam Samanta
Journal:  Brain Dev       Date:  2020-09-04       Impact factor: 1.961

Review 4.  Abnormalities of the DNA methylation mark and its machinery: an emerging cause of neurologic dysfunction.

Authors:  Jacqueline Weissman; Sakkubai Naidu; Hans T Bjornsson
Journal:  Semin Neurol       Date:  2014-09-05       Impact factor: 3.420

5.  Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice.

Authors:  Heather A Born; An T Dao; Amber T Levine; Wai Ling Lee; Natasha M Mehta; Shubhangi Mehra; Edwin J Weeber; Anne E Anderson
Journal:  Sci Rep       Date:  2017-08-16       Impact factor: 4.379

6.  Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.

Authors:  N A Copping; J L Silverman
Journal:  Mol Autism       Date:  2021-02-06       Impact factor: 7.509

Review 7.  Clinical characteristics and epilepsy in genomic imprinting disorders: Angelman syndrome and Prader-Willi syndrome.

Authors:  Tzong-Shi Wang; Wen-Hsin Tsai; Li-Ping Tsai; Shi-Bing Wong
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2019-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.